At Evopoint, we are committed to integrating novel and emerging technologies across diverse discovery platforms and modalities.
Evopoint adopts a disease-centered approach. We identify and establish the optimal technology platforms and modalities tailored to our desired target, indication, and patient population to ensure efficacy, safety, and druggability of candidate therapies.
Small Molecule Platform
Our Small Molecule Platform leverage cutting-edge technologies and innovative mechanisms of action (MOA) to discover SM therapies for cancer, bacterial infections, and other debilitating diseases. By combining innovative science with a systematic approach, our Small Molecule Platform are designed to deliver differentiated therapies with strong clinical potential and meaningful patient impact.
Target Protein Degrader
Our TPD platform focuses on UPS-dependent PROTAC technology to develop oral small molecular degraders for the degradation of high-value undruggable targets. We have successfully designed potent degraders with high oral bioavailability for the treatment of solid tumors and other diseases.
Other Novel Platforms
We are continuously evaluating new platforms or modalities (such as ADC) that can harness cutting-edge technologies to deliver effective therapeutics through unique MOA.
